MedTrace Logo

Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer

NCT04758780 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-02-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic triple negative breast cancer (TNBC) patients.

Conditions

Interventions

DRUG

89Zr-TLX250

89Zr-TLX250 PET/CT

Sponsors & Collaborators

  • Telix Pharmaceutical

    collaborator UNKNOWN

  • SIRIC ILIAD

    collaborator UNKNOWN

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • Caroline ROUSSEAU, MD · Institut de Cancerologie de l'Ousest - ICO

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-21
Primary Completion
2023-03-31
Completion
2023-09-13

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04758780 on ClinicalTrials.gov